aDivision of Cardiology, Department of Internal Medicine, Turin, Italy bDepartment of Cardiology, St.Joseph's Regional Medical Center, Paterson, New Jersey cDivision of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, California, USA dDivision of Interventional Cardiology, Instituto Cardiovascular, Hospital La Paz, Paseo La Castellana, Madrid, Spain eDepartment of Medico-Surgical Sciences, Biotechnologies Sapienza University of Rome, Italy fInvasive Cardiology, Campus Middelheim, Antwerpen, Belgium gMeta-analysis and Evidence based medicine Training in Cardiology, Italy.
J Cardiovasc Med (Hagerstown). 2013 Nov;14(11):773-9. doi: 10.2459/JCM.0b013e3283619410.
Developed countries are facing a sustained increase in life expectancy. Along with all social and cultural implications of increase lifespan, very elderly patients are undergoing percutaneous coronary intervention (PCI) with increasing frequency. However, there is limited evidence to guide clinicians in evaluating pros and cons of PCI in this very frail patient population. We, thus, aimed to perform a systematic review and meta-analysis of clinical studies reporting on PCI with stenting in nonagenarians.
Studies reporting on five or more nonagenarians undergoing PCI were systematically searched in PubMed (last updated on November 2011). Baseline and clinical characteristics, in-hospital and long-term outcomes were systematically appraised. End points of interest were in-hospital and long-term follow-up incidence of death and Major Adverse Cardiac Events (MACE; i.e. the composite of death from all causes, myocardial infarction or repeat revascularization). Events were pooled with a random-effect model, generating summary estimates of incidence rates [95% confidence intervals (CI)].
A total of 10 studies were included, reporting on a total of 575 nonagenarians undergoing PCI with stenting who represented 1.99% (1.34-2.5) of those undergoing revascularization in the cath lab in a mean period of 5 (3-7) years. Twenty-three percent (13-45) of patients presented with STEMI (ST Segment Elevation Myocardial Infarction), 10% (7-12) with cardiogenic shock and in 78% (64-88) of cases a multivessel disease was diagnosed. Meta-analytic pooling of event rates showed an in-hospital death risk of 12.61% (9.71-15.50) with MACE in 16.41% (13.36-19.47). After a follow-up ranging from 6 to 29 months (median 12), the risk of long-term death was 31.00% (17.10-45.52), with MACE in 37.00% (19.56-55.95; all CI 95%).
Our meta-analysis, pooling the largest cohort ever of nonagenarians undergoing PCI with stents, confirms the feasibility of percutaneous coronary stenting even in this very frail patient subset, despite the expected severe event attrition during follow-up. Thus, nonagenarians with an acceptable risk profile, recent clinical instability and/or disabling symptoms should not be denied the possibility of percutaneous coronary revascularization.
发达国家的预期寿命持续延长。随着寿命延长带来的所有社会和文化影响,非常高龄的患者接受经皮冠状动脉介入治疗(PCI)的频率也越来越高。然而,目前仅有有限的证据可以指导临床医生评估 PCI 在这一非常脆弱的患者群体中的利弊。因此,我们旨在对报告高龄(≥ 90 岁)患者行 PCI 及支架置入术的临床研究进行系统评价和荟萃分析。
我们系统检索了 PubMed 数据库中报告≥ 5 例高龄患者行 PCI 及支架置入术的研究(最后更新日期为 2011 年 11 月)。系统评估了患者的基线和临床特征、住院和长期预后。研究的主要终点为住院期间和长期随访期间的死亡率和主要不良心脏事件(MACE;即所有原因死亡、心肌梗死或再次血运重建的复合终点)发生率。采用随机效应模型汇总计算发生率(95%可信区间)。
共纳入 10 项研究,共纳入 575 例行 PCI 及支架置入术的高龄患者,占同期行血运重建患者的 1.99%(1.34%-2.5%),平均随访时间为 5 年(3-7 年)。23%(13%-45%)的患者为 ST 段抬高型心肌梗死(STEMI),10%(7%-12%)为心原性休克,78%(64%-88%)的患者存在多支血管病变。对事件发生率进行荟萃分析显示,住院期间死亡率为 12.61%(9.71%-15.50%),MACE 发生率为 16.41%(13.36%-19.47%)。中位随访时间为 12 个月(6-29 个月)时,长期死亡率为 31.00%(17.10%-45.52%),MACE 发生率为 37.00%(19.56%-55.95%;所有 CI 95%)。
本荟萃分析纳入了迄今最大规模的高龄患者 PCI 及支架置入术队列,证实即使在这一非常脆弱的患者亚组中,经皮冠状动脉支架置入术也是可行的,尽管在随访期间预期会出现严重的事件丢失。因此,对于风险可接受、近期临床不稳定和/或有症状的高龄患者,不应剥夺其接受经皮冠状动脉血运重建的可能性。